



DATE	ACTION/DESCRIPTION	
12/13/2023	New policy for Adzyna created.	

References:

1. Adzyna [prescribing information]. Takeda Pharmaceuticals U.S.A., Inc.
2. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for the diagnosis of thrombocytopenic purpura [published correction appears in *J Thromb Haemost*. 2021 May 2020;18(10):2486-2495. doi:10.1111/jth.15006
3. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombocytopenic purpura. *J Thromb Haemost*. 2020;18(10):2496-2502. doi:10.1111/jth.15006
4. Jain N, Oldenburg J, Ozelo MC, Sun SX, Tang L, Tzivelekis S. Recent advances in treatment options for rare hemostatic disorders: selected poster extracts of recent research in hemophilia A, congenital hemophilia with inhibitors, von Willebrand disease, and thrombotic thrombocytopenic purpura presented at the 29th congress of the International Society on Thrombosis and Haemostasis (ISTH 2021, Jul 17-21; virtual congress). *Expert Rev Hematol*. 2022;15(sup1):1-18. doi:10.1080/17474086.2022.2074395